Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

2C-CPe

Add links
From Wikipedia, the free encyclopedia
2C-CPe
Clinical data
Other names2C-CPE; 4-Cyclopentyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-cyclopentylphenethylamine
Identifiers
  • 2-(4-cyclopentyl-2,5-dimethoxyphenyl)ethanamine
PubChem CID
Chemical and physical data
FormulaC15H23NO2
Molar mass249.354 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)C2CCCC2
  • InChI=1S/C15H23NO2/c1-17-14-10-13(11-5-3-4-6-11)15(18-2)9-12(14)7-8-16/h9-11H,3-8,16H2,1-2H3
  • Key:GIYHLPFOZWFVHO-UHFFFAOYSA-N

2C-CPe, also known as 4-cyclopentyl-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a moderately potent agonist at the serotonin receptor 5-HT2A in vitro, with a binding affinity (Ki) of 134 nM, slightly weaker than the related cyclopropyl compound 2C-CP. It is not known to have been tested in humans or animals.[1] It is a controlled substance in Canada under phenethylamine blanket-ban language.[2]

See also

[edit]

References

[edit]
  1. ↑ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
  2. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=2C-CPe&oldid=1338568892"